Kite Pharma Inc  

(Public, NASDAQ:KITE)   Watch this stock  
Find more results for NIHC, Inc.�
53.14
+1.93 (3.77%)
After Hours: 53.20 +0.06 (0.11%)
May 27, 7:54PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 50.06 - 53.26
52 week 21.00 - 89.21
Open 51.70
Vol / Avg. 0.00/1.19M
Mkt cap 2.27B
P/E     -
Div/yield     -
EPS -1.27
Shares 43.06M
Beta     -
Inst. own 72%
May 19, 2015
Kite Pharma Inc at UBS Global Healthcare Conference
May 15, 2015
Q1 2015 Kite Pharma Inc Earnings Release
May 6, 2015
Kite Pharma Inc at Credit Suisse Antibody Day
Mar 26, 2015
Q4 2014 Kite Pharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -523.71% -
Operating margin -539.74% -
EBITD margin - -
Return on average assets -14.05% -21.62%
Return on average equity -16.16% -22.73%
Employees 72 -
CDP Score - -

Address

2225 COLORADO AVENUE
SANTA MONICA, CA 90404
United States - Map
+1-310-8249999 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT). eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs, or T cell receptors, or TCRs). These modified T cells are designed to recognize and destroy cancer cells. The Company funds multiple Phase I-2a clinical trials with CAR- and TCR-based therapies that are being conducted by its collaborator, the Surgery Branch of the National Cancer Institute (NCI). The Company plans to conduct a Phase I-2 clinical trial for its lead product candidate KTE-C19, a CAR-based therapy, in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL).

Officers and directors

Arie S. Belldegrun M.D. Executive Chairman of the Board, President, Chief Executive Officer, Founder
Age: 65
Bio & Compensation  - Reuters
Cynthia M. Butitta Chief Financial Officer, Chief Operating Officer
Age: 60
Bio & Compensation  - Reuters
David Chang M.D., Ph.D. Executive Vice President - Research and Development, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Helen S. Kim Executive Vice President - Business Development
Age: 52
Bio & Compensation  - Reuters
Margo R. Roberts Ph.D. Chief Scientific Officer
Age: 59
Bio & Compensation  - Reuters
Marc D. Better Ph.D. Vice President - Product Sciences
Age: 59
Bio & Compensation  - Reuters
Rizwana F. Sproule Vice President - Regulatory Affairs
Age: 52
Bio & Compensation  - Reuters
Jeffrey Wiezorek M.D. Vice President - Clinical Development
Age: 43
Bio & Compensation  - Reuters
David Bonderman J.D. Lead Independent Director
Age: 73
Bio & Compensation  - Reuters
Joshua A. Kazam Director
Age: 38
Bio & Compensation  - Reuters